Prior to the introduction and availability of imatinib, only 28 percent of patients went on to receive an allogeneic stem cell transplant per the study protocol. In these pre-imatinib patients, five-year overall survival was 40 percent for those patients who received an allogeneic stem cell transplant compared with 19 percent for non-transplanted patients. Of patients in the "late" and "early" arms who received imatinib, 44 percent were able to undergo the allogeneic stem cell transplant. Three-year overall survival was 59 percent for these transplant patients compared with 28 percent for those who did not receive a transplant.
"The Philadelphia chromosome is the single most common chromosome abnormality for adults with ALL, and therefore it is important to know that a targeted therapy like imatinib can help improve outcomes in these patients," said lead study author Adele K. Fielding, MBBS, PhD, FRCPath, FRCP, Senior Lecturer, University College London. "These study results demonstrate for the first time that there is a long-term survival advantage of being treated with imatinib earlier in the treatment protocol."
Dr. Fielding will present this study in an oral presentation on Monday, December 6, at 7:00 a.m. in Room 311 ABCD.
Excellent Outcomes at 3 Years With Nilotinib 800 mg Daily in Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial
Contact: Lindsey Love
American Society of Hematology
Related medicine news :
1. MSU researcher linking breast cancer patients with alternative therapies
2. Notch-blocking drugs kill brain cancer stem cells, yet multiple therapies may be needed
3. ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
4. NIH/NHLBI-funded PACT Group Announces the Renewal of Production Assistance for Cellular Therapies (PACT)
5. ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes
6. Intense Cholesterol, Blood Pressure Therapies Dont Help Type 2 Diabetics
7. Study evaluates costs and benefits associated with new colon cancer therapies
8. New therapies increase survival rates in post-transplant liver cancer patients
9. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
10. Molecular discovery points to new therapies for brain tumors
11. Ovarian cancer study offers vital clues for new therapies